Your browser doesn't support javascript.
loading
Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers.
Montero-Conde, Cristina; Leandro-García, Luis Javier; Martínez-Montes, Ángel M; Martínez, Paula; Moya, Francisco J; Letón, Rocío; Gil, Eduardo; Martínez-Puente, Natalia; Guadalix, Sonsoles; Currás-Freixes, Maria; García-Tobar, Laura; Zafon, Carles; Jordà, Mireia; Riesco-Eizaguirre, Garcilaso; González-García, Patricia; Monteagudo, María; Torres-Pérez, Rafael; Mancikova, Veronika; Ruiz-Llorente, Sergio; Pérez-Martínez, Manuel; Pita, Guillermo; Galofré, Juan Carlos; Gonzalez-Neira, Anna; Cascón, Alberto; Rodríguez-Antona, Cristina; Megías, Diego; Blasco, María A; Caleiras, Eduardo; Rodríguez-Perales, Sandra; Robledo, Mercedes.
Affiliation
  • Montero-Conde C; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Leandro-García LJ; Biomedical Research Networking Centre on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain.
  • Martínez-Montes ÁM; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Martínez P; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Moya FJ; Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Letón R; Molecular Cytogenetics Unit, Human Cancer Genetics Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
  • Gil E; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Martínez-Puente N; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Guadalix S; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Currás-Freixes M; Biomedical Research Networking Centre on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain.
  • García-Tobar L; Department of Endocrinology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Zafon C; Department of Endocrinology, Clínica Universidad de Navarra, Madrid, Spain.
  • Jordà M; Familial Cancer Clinical Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Riesco-Eizaguirre G; Anatomical Pathology Section, Clínica Universidad de Navarra, Pamplona, Spain.
  • González-García P; Department of Endocrinology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Monteagudo M; Program for Predictive and Personalized Medicine of Cancer (PMPPC), Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Torres-Pérez R; Department of Endocrinology and Nutrition, Hospital Universitario de Móstoles, Madrid, Spain.
  • Mancikova V; Endocrinology Molecular Group, Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain.
  • Ruiz-Llorente S; Histopathology Unit, Biotechnology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
  • Pérez-Martínez M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Pita G; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Galofré JC; Bioinformatics for Genomics and Proteomics, National Centre for Biotechnology (CNB-CSIC), Madrid, Spain.
  • Gonzalez-Neira A; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Cascón A; Department of Biomedicine and Biotechnology, Universidad de Alcalá (UAH), Alcalá de Henares, Spain.
  • Rodríguez-Antona C; Confocal Microscopy Unit, Biotechnology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
  • Megías D; CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Blasco MA; Department of Endocrinology, Clínica Universidad de Navarra, Pamplona, Spain.
  • Caleiras E; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
  • Rodríguez-Perales S; Biomedical Research Networking Centre on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain.
  • Robledo M; CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Clin Transl Med ; 12(8): e1001, 2022 08.
Article de En | MEDLINE | ID: mdl-35979662
ABSTRACT

BACKGROUND:

Comprehensive molecular studies on tumours are needed to delineate immortalization process steps and identify sensitive prognostic biomarkers in thyroid cancer. METHODS AND

RESULTS:

In this study, we extensively characterize telomere-related alterations in a series of 106 thyroid tumours with heterogeneous clinical outcomes. Using a custom-designed RNA-seq panel, we identified five telomerase holoenzyme-complex genes upregulated in clinically aggressive tumours compared to tumours from long-term disease-free patients, being TERT and TERC denoted as independent prognostic markers by multivariate regression model analysis. Characterization of alterations related to TERT re-expression revealed that promoter mutations, methylation and/or copy gains exclusively co-occurred in clinically aggressive tumours. Quantitative-FISH (fluorescence in situ hybridization) analysis of telomere lengths showed a significant shortening in these carcinomas, which matched with a high proliferative rate measured by Ki-67 immunohistochemistry. RNA-seq data analysis indicated that short-telomere tumours exhibit an increased transcriptional activity in the 5-Mb-subtelomeric regions, site of several telomerase-complex genes. Gene upregulation enrichment was significant for specific chromosome-ends such as the 5p, where TERT is located. Co-FISH analysis of 5p-end and TERT loci showed a more relaxed chromatin configuration in short telomere-length tumours compared to normal telomere-length tumours.

CONCLUSIONS:

Overall, our findings support that telomere shortening leads to a 5p subtelomeric region reorganization, facilitating the transcription and accumulation of alterations at TERT-locus.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de la thyroïde / Telomerase Type d'étude: Diagnostic_studies / Prognostic_studies Limites: Humans Langue: En Journal: Clin Transl Med Année: 2022 Type de document: Article Pays d'affiliation: Espagne

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de la thyroïde / Telomerase Type d'étude: Diagnostic_studies / Prognostic_studies Limites: Humans Langue: En Journal: Clin Transl Med Année: 2022 Type de document: Article Pays d'affiliation: Espagne
...